Premium
Chemical‐viral co‐carcinogenesis: Requirement for leukemia virus expression in accelerated transformation
Author(s) -
Mishra Nirmal K.,
Pant Kamala J.,
Thomas Francina O.,
Price Paul J.
Publication year - 1976
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910180618
Subject(s) - carcinogen , carcinogenesis , virus , puromycin , transformation (genetics) , biology , virology , malignant transformation , ethidium bromide , leukemia , interferon , cancer research , microbiology and biotechnology , chemistry , protein biosynthesis , dna , biochemistry , genetics , gene
The essential role of Rauscher leukemia virus (RLV) multiplication in viral—chemical co‐carcinogenesis was investigated by the use of ethidium bromide (EtBr) as an inhibitor of viral complementary DNA (cDNA) integration in the host genome. EtBr inhibited co‐carcinogenic transformation when present at the time of RLV inoculation but was ineffective when added to preinfected cells. Inhibitors of protein synthesis, puromycin and cyclohexamide also inhibited co‐carcinogenic transformation of chronically infected cells. Purified rat interferon used at a concentration which inhibited 85% of RLV production did not modify the course of co‐carcinogenic transformation. The implications of these observations in terms of the possible role of the virus‐specific protein(s) in the co‐carcinogenic process are discussed.